Agents acting on the renin-angiotensin system: usage in Croatia during a seven-year period (CROSBI ID 558171)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Vitezić, Dinko ; Matana Kaštelan, Zrinka ; Buble, Tonći ; Vitezić Miomira ; Kovačević Miljenko ; Mršić Pelčić, Jasenka ; Župan, Gordana
engleski
Agents acting on the renin-angiotensin system: usage in Croatia during a seven-year period
Introduction In the contemporary world, particularly in developing countries, cardiovascular (CV) diseases are a major health care problem. CV and cerebrovascular diseases were the cause of over 50% of deaths in Croatia in 2004. Adequate therapy of these diseases, which includes usage of drugs acting on renin-angiotensin system (RAS), leads to reduction of CV and cerebrovascular morbidity and mortality. These drugs are used in management of variety of cardiovascular disorders and established their significance in hypertension, heart failure, stoke prevention, managing asymptomatic and symptomatic left-ventricular dysfunction, and diabetes. Prescribing of ACE inhibitor group in the treatment of hypertension during the last decade is among the highest in general (family) practice. The aim of our study was to identify and analyze changes in the use of drugs acting on RAS in Croatia during the seven-year period (2001-2007). Methods The data concerning drugs usage prescribed by GPs during the period from 2001 to 2007 were collected from the Croatian Health Insurance Institute (CHII). CHII maintains a database on drugs prescribed by primary health care physicians and dispensed by pharmacies. This database does not include non-prescription drugs, drugs paid by patients or in-hospital used drugs. According to the World Health Organization Collaborating Centre for Drugs Statistics Methodology annual volumes of drugs are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data are presented in Euros (€). An average cost per DDD was calculated for this group of drugs. Results Agents acting on the RAS for the seven-year period remained the most prescribed CV drug group with the largest cost share. The use of the whole group increased 115% (from 56.07 to 120.55 DDD/1000) while the related expenses increased 53.5%. The consumption and cost shares of ACE inhibitors (plain and combined) decreased (from 98% to 88% and from 96% to 90%, respectively). The use of the combinations of ACE inhibitors and diuretics increased from 10.07 to 41.90 DDD/1000 and angiotensin receptor blockers and diuretics from 0 to 6.42 DDD/1000. The average cost per DDD for the investigated group dropped from 0.33 to 0.24 €/DDD. Conclusion During the investigated period the usage of the group of agents acting on the RAS increased considerably. The related growth of financial expenditure increased at a slower rate. The average cost per DDD gradually decreased mainly as the result of the introduction of generics and the implementation of restrictive measures on the Croatian drug market.
cardiovascular diseases; drugs acting on renin-angiotensin system; drugs usage; seven-year period
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
343-343.
2009.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Value in health
1098-3015
Podaci o skupu
Twelfth Annual European Congress of International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
poster
24.10.2009-27.10.2009
Pariz, Francuska
Povezanost rada
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita